ISIS-SMNRx: Phase I started

Isis began an open-label, dose-escalation, U.S. Phase I trial to evaluate 4 doses of intrathecal ISIS-SMNRx in about 24 patients ages 2-14 years. ISIS-SMNRx has Fast Track and Orphan Drug designation ...